Cell therapy has come forward as a recent phase of the biotechnology revolution in medical sector. As cell therapy is based on ground-breaking scientific discoveries and various technological advancements. The main aim of cell therapy is to target various diseases at the cellular level by restoring a certain cell population as carriers of therapeutic cargo. It is also used in combination with gene therapy for many diseases. For many diseases, gene and cell therapy are applied in combination.
With new technologies, and different types of cells such as hematopoietic stem cells (HSC), mesenchymal stem cells, skeletal muscle stem cells, lymphocytes, pancreatic islet cells, and dendritic cells, cell therapy can be used for the treatment of a variety of diseases. Hematopoietic stem cell transplantation or Bone marrow transplant is the most commonly used cell therapy to treat a variety of hematologic conditions and blood cancers. Potential applications of cell therapy include treatment of cancers, urinary problems, autoimmune disease, and infectious disease, repairing spinal cord injuries, rebuilding damaged cartilage in joints, improving the immune system, and treatment of neurological disorders.
Adipose tissue-derived stem cells (ADSCs) are another most promising cell types for application in regenerative therapies. Regenerative medicine is an interdisciplinary field comprises of tissue engineering, with an objective of restoration or establishment of the normal functioning of organs.
Get a sample report at https://www.marketresearchfuture.com/sample_request/5066 .
Some of key the players in the cell therapy market are Novartis AG, GlaxoSmithKline plc, MEDIPOST, Osiris, PHARMICELL, NuVasive, Inc., JCR Pharmaceuticals Co., Ltd, ANTEROGEN.CO.,LTD., Cynata, CELLECTIS, BioNTech IMFS, EUFETS GmbH, Cognate, Pluristem, Grupo Praxis, Genzyme Corporation, Advanced Tissue and others.
It is estimated that cell therapy market is expected to grow at a CAGR 10.6% during the forecast period of 2017-2023.
Around the world stem cell therapy, and related products are being regulated by various guidelines and laws based on the regulatory agencies in charge, i.e. the Food and Drug Administration (FDA) in the USA, the European Medicines Agency (EMA) in Europe, different and other regional authorities. According to a study published in Transfusion Medicine and Hemotherapy in 2016, it is found that the therapeutic products based on gene therapy, and somatic cell therapy are defined as advanced therapy medicinal products (ATMP), in Europe.
Notably, rising prevalence of chronic disorders is the key factor driving the cell therapy market. According to a study published in Neurology India journal in 2014, it is found that out of total population of India, around 30 million people were suffering from neurological disorders.
Various other push factors such as increasing geriatric population, increasing government assistance, replacement of animal testing model, technological advancements, and improvement in regulatory framework continuously contribute to the growth of the global cell therapy market. As per the instructions suggested by the FDA on the regulation of tissue engineering, the purity and quality of engineered tissue should be maintained and regulated to avoid any kind of chemical instability.
Despite these drivers, there are some issues associated with cell therapy market. Challenges in research and development, the high cost of manufacturing, and poor healthcare system in low and middle-income countries may hinder the growth of the market to an extent.
Browse Complete Report at https://www.marketresearchfuture.com/reports/cell-therapy-market-5066 .
The Americas dominate the cell therapy market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in cell therapy market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.
The Asia Pacific is the fastest growing cell therapy market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014–15.
The Middle East & Africa has the lowest market for cell therapy due to lack of technical knowledge and poor medical facilities.
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
P: +1 646 845 9312